Outsourced Pharma

Should you keep stability storage and testing in-house or outsource to a reliable partner? This webinar on December 4th will discuss risk mitigation, data quality, and cost management when outsourcing stability studies, along with best practices for protocol creation and risk assessment. ?? Reserve your spot for the discussion: https://lnkd.in/en3_6men ??? Speakers: Stephen Delaney, Managing Director, Q1 Scientific, a Cambrex company Darryl Souness, Head of Analytical, Cambrex Edinburgh

Should you keep stability storage and testing in-house or outsource to a reliable partner? This webinar NEXT WEEK (12/4) will discuss risk mitigation, data quality, and cost management when outsourcing stability studies, along with best practices for protocol creation and risk assessment. ?? Secure your spot for the discussion: https://lnkd.in/ebQytewf ?? Key Takeaways: ? Risk mitigation and cost management when outsourcing stability storage ? Data quality when working with a reliable outsourced partner ? Creation of thorough stability study protocols, with contingencies built in, and review of methods to assess risk ? Cost savings for multiple batch studies

Join us NEXT WEEK (12/3) to learn about best practices and strategies to optimize bioconjugate drug product tech transfers and supplies in clinical or commercial phase. ?? Reserve your spot for the discussion: https://lnkd.in/e_uN9GnQ Lonza experts will explore real-world case studies highlighting: ? Innovative solutions to accelerate clinical tech transfer for bioconjugates drug products and supported by science-driven development approaches ? Tailored approaches from different entry points and either as stand-alone or as part of integrated bioconjugates drug substance/drug product solutions

WEBINAR NEXT WEEK! Join us on December 2nd to explore the development steps at Lonza that lead to an mRNA construct optimized for your own requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development of your mRNA project. ?? Secure your spot for the discussion: https://lnkd.in/dD7BrWC7 ?? Key Takeaways: ? Understand the criticality of cGMP manufacturing considerations in Preclinical Process Development of mRNA and LNP formulations ? Get insights into the Analytical and Process Development Activities required to transition from Research to cGMP manufacturing ? Learn about advancements in the Analytics of mRNA and LNP projects

Hear some initial thoughts from Praveen Prasanna on putting discussions with your CDMO into details in a contract that makes both you and your CDMO want to work together: https://lnkd.in/dnVZgWRE

One of the key concerns for many biopharmaceutical companies is minimizing environmental impact. Learn about additive manufacturing and the significant advantages it offers to biomanufacturers. https://lnkd.in/dyf4JYbx By Fernando Polanco, Principal Eco Design Specialist, Cytiva

This webinar provides an introduction to developing continuous chromatography using Simulated Moving Bed (SMB) Technology for small molecule applications. Key benefits include rapid development, easy scale-up, cGMP compliance, cost-effectiveness, and sustainability. Attendees will learn the basics of SMB, its advantages over other technologies, and its sustainability benefits. #SKpharmteco #chromatography #SMB

View the latest Contract Manufacturing: Opportunities and Threats report to identify CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections: https://lnkd.in/eEpPUMzw Each month, Outsourced Pharma works in conjunction with?PharmSource, part of GlobalData Plc, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers.

Join us on December 3rd to learn about best practices and strategies to optimize bioconjugate drug product tech transfers and supplies in clinical or commercial phase. ?? Secure your spot for the discussion: https://lnkd.in/eHZGSzyJ ?? Key Learning Objectives:? ? Explore Best Practices and Case Studies in bioconjugates and ADC drug product development and manufacturing ? Learn about Lonza new Drug Product High Potent capabilities from pre-clinical development to commercial supply ? Find out about the flexible entry points with unique tailored approaches for every ADC phase